Frequent deletions and down-regulation of micro- RNA genes <i>miR15</i> and <i>miR16</i> at 13q14 in chronic lymphocytic leukemia

DOI Web Site 被引用文献103件
  • George Adrian Calin
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Calin Dan Dumitru
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Masayoshi Shimizu
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Roberta Bichi
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Simona Zupo
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Evan Noch
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Hansjuerg Aldler
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Sashi Rattan
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Michael Keating
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Kanti Rai
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Laura Rassenti
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Thomas Kipps
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Massimo Negrini
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Florencia Bullrich
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA
  • Carlo M. Croce
    Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA 19107 USA; Clinical Immunology, National Institute for Research on Cancer, 16132 Genoa, Italy Europe; Department of Leukemia, University of Texas M. D. Anderson Cancer Center, Houston, TX 77030 USA; Long Island Jewish Medical Center, New Hyde Park, NY 11040 USA; and Department of Medicine, University of California at San Diego, La Jolla, CA 92093 USA

抄録

<jats:p> Micro-RNAs ( <jats:italic>miR</jats:italic> genes) are a large family of highly conserved noncoding genes thought to be involved in temporal and tissue-specific gene regulation. MiRs are transcribed as short hairpin precursors (≈70 nt) and are processed into active 21- to 22-nt RNAs by Dicer, a ribonuclease that recognizes target mRNAs via base-pairing interactions. Here we show that <jats:italic>miR15</jats:italic> and <jats:italic>miR16</jats:italic> are located at chromosome 13q14, a region deleted in more than half of B cell chronic lymphocytic leukemias (B-CLL). Detailed deletion and expression analysis shows that <jats:italic>miR15</jats:italic> and <jats:italic>miR16</jats:italic> are located within a 30-kb region of loss in CLL, and that both genes are deleted or down-regulated in the majority (≈68%) of CLL cases. </jats:p>

収録刊行物

被引用文献 (103)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ